Megastar gains additional performers three weeks from launch

|

Published 08-JUN-2017 22:51 P.M.

|

1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

With only three weeks until the launch of its Megastar competition, leading digital technology and entertainment company, MSM Corporation International (ASX:MSM) has signed three additional sponsored performers under its agreement with Los Angeles-based Fullscreen Media (fullscreenmedia.co).

This brings Megastar’s cast of sponsored performers and social influencers to a total of 48, equating to a total audience reach of more than 36 million.

MSM’s target is to reach 80 million, but given the product is yet to go live this level of audience participation provides a robust base for further growth.

However MSM is an early stage play and investors should seek professional financial advice if considering this stock foe their portfolio.

In addition to performing as sponsored talent in the competition, the new influencers will leverage their social media followings to drive brand awareness and user engagement for the Megastar competition.

Social media influencers bring a large, instantly accessible and highly invested audience, and potential A-list celebrities will enhance the competition’s mainstream media appeal, enabling it to reach a broader audience beyond its primary target of 18 to 40 year olds.

On this note, MSM Executive Director Asia-Pacific, Sophie McGill said, “Megastar is now in the final phases of discussions with A-list celebrities, as another method that allows for the amplification of marketing spend”.

MSM’s shares have traded in a tight range between 20 cents and 25 cents over the last month, and while there may be a hiatus leading up to June 30 there is the potential for share price catalysts to emerge in July/August.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X